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A 45-Year-Old Male with HIV, Kaposi’s Sarcoma, and
Squamous Cell Carcinoma of the Skin
Jascha Rubin, MD and Hasan Bayat, MD

Case
A 45-year-old male with a history of human immunodeficiency
virus, (HIV), on highly active antiretroviral therapy (HAART),
Kaposi’s sarcoma, and squamous cell carcinoma (SCC) of the
right lower extremity complicated by chronic wound formation
presented with worsening right leg pain and increasing wound
drainage.
The patient described the pain as excruciating, with 10/10
intensity and exacerbated by movement. His wounds began
draining purulent material and blood about two weeks prior to
presentation. He has had several similar, though milder episodes
in the past requiring hospitalization. When the wounds began
to have a foul odor, he presented to the hospital. On review of
systems, the patient reported new-onset back pain that began
approximately one week prior to admission. The pain was
constant, sharp, worse with movement, and had an insidious
onset. He also had a recent 30 lb weight loss with worsening
fatigue. He denied fevers and chills.
His medical history included HIV and Kaposi’s sarcoma in the
right groin, both diagnosed concomitantly five years ago. Soon
after diagnosis he had been started on HAART, and underwent
chemotherapy with paclitaxel and liposomal doxorubicin. He
subsequently developed multiple wounds spreading over his
right leg. These became complicated by recurrent infections with
methicillin resistant Staphylococcus aureus (MRSA) requiring
surgical debridement and intravenous antibiotics. Two months
prior to admission his wounds were biopsied and pathology
revealed a poorly differentiated SCC. He continued to undergo
wound management as an outpatient while plans were made to
reevaluate his new malignancy. His medications on admission
included Atripla, hydromorphone, fluconazole, TMP-SMX,
omeprazole, ondansetron, and ibuprofen.
The patient lived at home with his same sex partner. He worked
in the restaurant business before becoming disabled. He had
recently quit smoking but has a 20 pack year history, a remote
history of cocaine abuse, and was a social alcohol consumer. His
family history was notable for diabetes and hypertension.
On physical exam, the patient’s vital signs were all within
normal limits. He was a frail man with temporal wasting. He
was in no acute distress and was alert and oriented. His mucous
membranes were dry without evidence of thrush. He had no
cervical or supraclavicular lymphadenopathy. His cardiovascular, pulmonary, and abdominal exams were unremarkable.
There was diffuse tenderness to palpation over the thoracic and
lumbar spine. On his right lower extremity there were confluent,
raised, macerated tumors, extending from the knee to ankle, with
involvement of his plantar foot, 2nd, and 3rd digits (Figure 1). A
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foul smelling, sero-sanguinous drainage was observed emanating
from these growths.
On admission, laboratory studies were notable for a white
blood cell count of 11.1x109/L, hemoglobin of 7.8 mg/dL,
platelets of 409 x 109/L. Serum chemistry was notable for
sodium of 127 mmol/L. His CD4 count was 208 cells/uL and
HIV viral load was 14,400 IU/mL. A computed tomography
(CT) scan of the chest, abdomen and pelvis revealed mural
thickening throughout the entire esophagus and proximal
stomach, retroperitoneal lymphadenopathy, and a pathologic
compression fracture at the level of L2. An magnetic resonance
imaging (MRI) of the right lower extremity demonstrated
innumerable subcutaneous fluid collections in the right leg,
with abscess formation in the antero-medial aspect of the
proximal leg eroding into the tibial cortex. There was diffuse
nodular skin thickening with enhancement around his tumors
(Figure 2). Wound cultures from his leg grew MRSA and
Pseudomonas aeruginosa.

Hospital Course
The patient required numerous packed red blood cells
transfusions, intravenous antibiotics, and aggressive wound care.
He underwent CT-guided biopsy of the pathologic lumbar spine
fractures. The pathology from these specimens was consistent
with metastatic SCC. The patient was seen in consultation by
surgery, medical oncology, radiation oncology, gastroenterology
and infectious disease. He was offered amputation of his leg, but
adamantly declined this option. He opted instead for a course of
palliative chemotherapy.

Discussion
Infection with HIV has long been known to increase the risk
of developing cancer. Classically these cancers are included
in the category of AIDS-defining illnesses, and are found in
patients with poor viral suppression. Among the well known
examples are Kaposi’s sarcoma, primary central nervous system
lymphoma, non-Hodgkin’s lymphoma, and invasive cervical
cancer. Mainstays of therapy for these malignancies have
always included HAART. The improved use and delivery of
HAART has prolonged the lifespan of HIV-infected patients.
In the post-HAART era there has been an increasing incidence
of non-AIDS-defining malignancies (NADM). These NADMs
have emerged as an important cause of morbidity and mortality
in the HIV-infected population.1-3
Since the mid-1990s the estimated number of AIDS-defining
cancers has decreased by greater than threefold, whereas the
number of NADMs has increased by approximately threefold.5
This increased incidence is partly a result of improved screening
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and diagnostic modalities for cancer, as well as patient longevity
and increased prevalence of HIV infection. However, NADMs,
after correcting for risk factors, have occurred in higher
incidences than in the general population, despite appropriate
viral suppression.1,4-6 One study by the American Cancer Society
showed that in the HIV population the rates of developing
NADMs within the United States was more than double that
of the general population, with a rate of 980 new NADMs per
100,000 person-years.7
The traditional risk factors for cancer, such as genetics and
carcinogen exposure, apply to patients with HIV-infection.
Incidence does not increase with low CD4 nadirs.7 NADMs
typically have a far more aggressive course than similar
malignancies in the general population. The exact mechanisms
responsible for the increased incidence and worse clinical course
of these malignancies in the HIV population remains unclear.3,7
CD4 lymphopenia, cell mediated immune dysfunction,
change in cytokine profile and role of HIV proteins, have
all been postulated to play a role in tumor development.10
Immunosuppression without CD4 depletion may also play a
role. This has been demonstrated by studies comparing organ
transplant recipients to the HIV population, both of whom
share a similar profile of cancer types and rates of occurence.8
A number of specific NADMs have been identified as having
increased incidence with HIV infection. These include anal
cancer, Hodgkin’s disease, head and neck cancers, testicular
cancer, prostate cancer, basal cell cancer, SCC of the skin, and
melanoma.3,7 Among these cancers, the cutaneous NADMs are
the most frequent, occurring at a rate of 6% in patients with HIV,
supplanting Kaposi’s sarcoma as the most common malignancy
in this population.9
SCC has been demonstrated in multiple case studies to be highly
aggressive in the setting of HIV. It presents at a significantly
younger age than non-HIV patients (44 versus 70 years), has
been associated with a high risk for local recurrence, metastasis,
and has a 50% mortality risk. 9-13 The major risk factors for
developing skin cancer with concomitant HIV infection are
mostly the same as in the general population, including fair-skin,
family history, and sun exposure.14 More than half of patients
diagnosed with SCC have a history of genital warts, suggesting
a possible link with human papillomavirus (HPV) infection.
However no direct link has yet been established between HPV
infection and SCC in HIV patients.10,15
The management of NADMs in patients with HIV can be
challenging for a variety of reasons. Patients with HIV often have
significant co-morbidities that can affect performance status
and treatment options. Staging the cancer can also be unreliable
in the setting of reactive lymphadenopathy typically found with
HIV infection. Other concerns include the combined toxicity of
chemotherapy and HAART, as well as the immunosupressive
effects of chemotherapy in already high-risk patients. Despite
these obstacles, management should involve an aggressive,
multidimensional approach. Therapy should include HAART,
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regardless of CD4 counts.16 Choices for chemotherapy should be
tailored to the patient and the tumor. Wide excisions with careful
analysis of margins should be performed to avoid recurrence.10
There should also be special attention to prophylaxis against
opportunistic infections while administering treatment.

Conclusion
Infection with HIV has long been associated with an increased
risk of developing cancer. In the post-HAART era, there has
been an increasing incidence of malignancies not classically
included in the category of AIDS-defining illnesses. This is
partly due to improved patient survival and cancer screening,
but is also linked to HIV infection itself. Most of these cancers
present at an earlier average age than in the general population,
and are highly aggressive. Heightened screening vigilance is thus
called for in the HIV population. Inclusion of HAART remains
a cornerstone of management, as does a highly aggressive and
multidisciplinary approach to managing the malignancy.
The morbidity and mortality due to aggressive SCC is dependent
on the initial control of the local or metastatic disease. Physicians
treating SCC should ensure that their patients receive adequate
resection with margin control. They should consider local or
regional adjunctive radiation and/or chemotherapy as well as
sentinel node procedures for high risk tumors. The initial CD4
count does not alter the approach to these cancers. Primary
prevention is essential to improved survival, so regular screening
exams and early biopsies of suspicious lesions are strongly
advocated.10
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“Torres Del Paine, Chile”
Photography by Jascha Rubin, MD

Demons and Dreams
Mariam Kabir, MD
Demons aplenty
In my life of scanty dreams
Demons aplenty
Taking away my beams.
Once in a while
They scatter away
And I see the light of day.
Once in a while
They leave me alone
And I see what may.
Demons aplenty
In my head of limited space
Crowding out thoughts of joy
Whispering acrimonies
Fears and bitter hitters
Leading me to
Yearn their banishment
From my head
Of limited space,
So I can see
Beams.
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